Patents Represented by Attorney John M. Petruncio
-
Patent number: 4744299Abstract: Disclosed is a liner-barrier system which is impermeable when cured to the igh concentrations of carboranyl burning rate accelerator which are incorporated into ultrahigh-burning rate propellants which are being developed for advanced interceptors. The liner-barrier composition, when uncured, comprises a polyvinyl butyral resin coblended with thermosetting resins, such as, phenolic, epoxy etc., that employs triphenylbismuthine as a quick cure catalyst, 4,5-epoxycyclohexylmethyl 4',5'-epoxycyclohexyl carboxylate and polyisocyanate as curative and crosslinking agents to further modify the liner-barrier formulation by reacting with the secondary hydroxyl groups. Further modification of the liner-barrier formulation is achieved by incorporation of aluminum powder to impart additional properties of impermeability. The uncured liner-barrier composition contains from 8.90 to about 10.21 weight percent solids in a solvent blend of isopropyl acetate and isopropyl alcohol which comprises from about 89.79 to about 91.Type: GrantFiled: April 1, 1983Date of Patent: May 17, 1988Assignee: The United States of America as represented by the Secretary of the ArmyInventor: David C. Sayles
-
Patent number: 4632830Abstract: A living, attenuated, oral vaccine system is described for the immunization gainst enteric disease. This oral vaccine is a genetic hybrid derivative of an attenuated galactose epimeraseless strain of S. typhi which carries at least one protective antigen other than normal somatic S. typhi antigens. The oral vaccine can provide protection against both typhoid fever and at least one other enteric disease. A bivalent oral vaccine is described wherein the non-typhoid protective antigen is the plasmid-encoded form I antigen of Shigella sonnei. A protective antigen from Shigella sonnei was transferred to a streptomycin resistant mutant of S. typhi strain Ty21a. The transconjugant S. typhi strain expressed both S. typhi and S. sonnei antigens and protected experimental animals against lethal infections with either S. typhi or S. sonnei. This strain is considered to be useful as a vaccine against typhoid fever and bacillary dysentery caused by S. sonnei. The mutated galactose epimeraseless S. typhi strain such as S.Type: GrantFiled: July 31, 1981Date of Patent: December 30, 1986Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Samuel B. Formal, Louis S. Baron, Dennis J. Kopecko
-
Patent number: 4554279Abstract: Improved means for the chemotherapy of malaria have been achieved with 5-oxy-primaquine analogues having the formula: ##STR1## wherein R.sub.4 represents hydrogen or a methyl grouping, and R represents an alkyl group containing 3 to 12 carbon atoms and pharmaceutically acceptable salts thereof, wherein the salt-forming acid may be organic or inorganic in nature. These primaquine-related compounds afford improvement in the chemotherapy of malaria by exerting plasmodicidal action on malaria parasites which may be present in either the blood, formed tissues, or blood and formed tissues of the mammalian host. Such broad and practical spectrum of effectiveness distinguishes the said primaquine analogues, which may be administered parenterally or perorally to infected animals.Type: GrantFiled: March 31, 1983Date of Patent: November 19, 1985Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Andrew J. Saggiomo, Edward A. Nodiff
-
Patent number: 4473494Abstract: A method for the production of stroma-free, non-heme protein-free hemoglo by use of zinc ion to promote precipitation of a zinc ion-bound insoluble hemoglobin complex, followed by membrane ultrafiltration of the zinc-hemoglobin complex from the filtrate fluid medium, preferably with a saline dialyzate.Type: GrantFiled: May 4, 1983Date of Patent: September 25, 1984Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Ross W. Tye
-
Patent number: 4473496Abstract: This invention relates to molecular modification of hemoglobin by utilizan of a class of .alpha., .omega.-dialdelhydes having a chain length of 5 to 7 members and substituted with at least one negatively charged group such as a phosphate moiety. A subject .alpha., .omega.-dialdehyde can be synthesized by sodium periodate oxidation of a phosphorylated ribose such as adenosine-5'-triphosphate or 5-phosphoribosyl-1-pyrophosphate. The compounds of this invention can be advantageously used for intramolecularly crosslinking hemoglobin for resuscitative purposes.Type: GrantFiled: October 28, 1983Date of Patent: September 25, 1984Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Patrick J. Scannon
-
Patent number: 4434168Abstract: The use of narcotic antagonists (e.g., naloxone) in shock therapy is disclosed.Type: GrantFiled: March 27, 1981Date of Patent: February 28, 1984Assignee: The United States of America as represented by the Secretary of the ArmyInventors: John W. Holaday, Alan I. Faden
-
Patent number: 4393048Abstract: Water soluble hydrogels of alkali metal alginate and glycerine have been found to be excellent wound dressings. The gels dry to an adherent, non-toxic pliable protective film which can be removed by water-washing when desired. The gels are also compatible with medicaments and hence can serve as vehicles or carriers for medicament application to wounds as well as a protective cover.Type: GrantFiled: October 30, 1981Date of Patent: July 12, 1983Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Arthur D. Mason, Jr., Avery A. Johnson, Jr., Harrel L. Walker, Eleanor G. Bowler, Charles R. Ritchey
-
Patent number: 4391498Abstract: A spectacle frame and method for providing eye protection during extreme physical activity through use of a spectacle frame comprising in combination rim means defining a pair of side-by-side viewing windows and having a recessed contoured bridge therebetween, temple yoke support means pivotally mounted to said rim means above and below each viewing window, and an expandable strap securing means connected to said temple yokes by means of slidable connector means which allow slidable adjustment of the angle of tilt of said frame relative to a wearer's face. In the preferred spectacle, the frame has a biconcave recessed bridge and the temple yokes are apertured to detachably mount on said rim means by snapping over temple pivot posts projecting upwardly and downwardly on said frame rim.Type: GrantFiled: July 20, 1979Date of Patent: July 5, 1983Inventor: Roy H. Rengstorff
-
Patent number: 4368194Abstract: The use of a mine boranes to inhibit the inflammation process is disclosed. hese boranes, which are boron analogs of .alpha.-amino acids, effectively block the following: general inflammation, induced arthritis, and the writhing reflex associated with inflammation pain. The inflammation associated with pleurisy is also inhibited. The boron analogs are shown in vitro to inhibit the release of lysosomal enzymes from liver and polymorphonuclear neutrophils (PMNs). Further, prostaglandin synthesis is blocked by these compounds at a low concentration, viz., 10.sup.-6 M.Liver oxidative phosphorylation processes are also uncoupled by these compounds, but PMN migration is unaltered at 10.sup.-4 M. The elevation of cyclic adenosine monophosphate in PMNs correlates positively with in vivo antiarthritic activity. Studies in rodents demonstrate that these boron analogs may be used at safe therapeutic doses. Several compounds per se are included within the scope of the invention.Type: GrantFiled: July 17, 1981Date of Patent: January 11, 1983Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Bernard F. Spielvogel, Andrew T. McPhail, Iris H. Hall
-
Patent number: 4346608Abstract: A float device is provided for density gradient fractionation which permits continuous removal of liquid samples from the surface of the liquid within a tube. The float device floats on the liquid surface and is provided with a centrally disposed length of tubing which extends through the device to provide communication between the liquid surface and a suction source such as a peristaltic pump. A concavity in the bottom of the float assists in removing trapped air and minimizes turbulent flow, thereby assuring high resolution of obtained samples.Type: GrantFiled: July 31, 1980Date of Patent: August 31, 1982Assignee: The United States of America as represented by the Secretary of the ArmyInventors: John G. Olenick, Patrick E. Lorenz
-
Patent number: 4345469Abstract: An air tunnel device is provided for use in combination with a thermohygrter of the type where the change of resistance of the probe in response to changes in the ambient atmosphere is used to measure the temperature and humidity of the atmosphere. The device includes a housing which defines an air passageway therethrough, a probe support for mounting the probe of the thermohygrometer so that the probe is exposed to the air passagement in the housing and a fan mounted in the housing below the probe support for drawing air into the air passageway and thus providing air flow at a constant velocity past the probe.Type: GrantFiled: October 3, 1980Date of Patent: August 24, 1982Assignee: The United States of America as represented by the Secretary of the ArmyInventors: James A. Devine, Jose A. Miletti
-
Patent number: 4312989Abstract: The use of amine boranes to inhibit the inflammation process is disclosed. These boranes, which are boron analogs of .alpha.-amino acids, effectively block the following: general inflammation, induced arthritis, and the writhing reflex associated with inflammation pain. The inflammation associated with pleurisy is also inhibited. The boron analogs are shown in vitro to inhibit the release of lysosomal enzymes from liver and polymorphonuclear neutrophils (PMNs). Further, prostaglandin synthesis is blocked by these compounds at a low concentration, viz, 10.sup.-6 M.Liver oxidative phosphorylation processes are also uncoupled by these compounds, but PMN migration is unaltered at 10.sup.-4 M. The elevation of cyclic adenosine monophosphate in PMNs correlates positively with in vivo antiarthritic activity. Studies in rodents demonstrate that these boron analogs may be used at safe therapeutic doses. Several compounds per se are included within the scope of the invention.Type: GrantFiled: August 21, 1979Date of Patent: January 26, 1982Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Bernard F. Spielvogel, Andrew T. McPhail, Iris H. Hall
-
Patent number: 4282253Abstract: An improved method is provided for the prevention of schistosomiasis in her animals. The topical application of a composition containing a dehydroabietylamine or a derivative thereof provides a coating of perdurable anti-penetrant through which the infective cercariae of the parasitic worm do not pass readily.Type: GrantFiled: November 14, 1979Date of Patent: August 4, 1981Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Edgar A. Steck
-
Patent number: 3949112Abstract: Fibrous materials such as textiles and paper are rendered oil and water resistant by treatment with polymers and copolymers of ##EQU1## wherein X and X' are halogen.Type: GrantFiled: November 19, 1973Date of Patent: April 6, 1976Assignee: Hooker Chemicals & Plastics CorporationInventor: Victor A. Pattison